ARF6-Mediated Endosome Recycling Reverses Lipid Accumulation Defects in Niemann-Pick Type C Disease by Schweitzer, Jill Kuglin et al.
ARF6-Mediated Endosome Recycling Reverses Lipid
Accumulation Defects in Niemann-Pick Type C Disease
Jill Kuglin Schweitzer, Sean D. Pietrini, Crislyn D’Souza-Schorey*
Department of Biological Sciences and the Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, Indiana, United States of America
Abstract
In human Niemann-Pick Type C (NPC) disease, endosomal trafficking defects lead to an accumulation of free cholesterol and
other lipids in late endosome/lysosome (LE/LY) compartments, a subsequent block in cholesterol esterification and
significantly reduced cholesterol efflux out of the cell. Here we report that nucleotide cycling or cellular knockdown of the
small GTP-binding protein, ARF6, markedly impacts cholesterol homeostasis. Unregulated ARF6 activation attenuates the
NPC phenotype at least in part by decreasing cholesterol accumulation and restoring normal sphingolipid trafficking. These
effects depend on ARF6-stimulated cholesterol efflux out of the endosomal recycling compartment, a major cell repository
for free cholesterol. We also show that fibroblasts derived from different NPC patients displayed varying levels of ARF6 that
is GTP-bound, which correlate with their response to sustained ARF6 activation. These studies support emerging evidence
that early endocytic defects impact NPC disease and suggest that such heterogeneity in NPC disease could result in diverse
responses to therapeutic interventions aimed at modulating the trafficking of lipids.
Citation: Schweitzer JK, Pietrini SD, D’Souza-Schorey C (2009) ARF6-Mediated Endosome Recycling Reverses Lipid Accumulation Defects in Niemann-Pick Type C
Disease. PLoS ONE 4(4): e5193. doi:10.1371/journal.pone.0005193
Editor: Jean Gruenberg, University of Geveva, Switzerland
Received November 7, 2008; Accepted March 13, 2009; Published April 14, 2009
Copyright:  2009 Schweitzer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by a pilot study initiative from the University of Notre Dame and a grant from the Leda J. Sears Trust to CDS. The
funders had no role in study design, data collection and analysis, decision to publish or preparation of manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: D’Souza-Schorey.1@nd.edu
Introduction
Cholesterol enters the endosomal recycling compartment
(ERC), a major repository of free cholesterol, via endocytosis
and non-vesicular mechanisms [1]. Cells acquire exogenous
cholesterol primarily through LDL-mediated endocytosis. The
LDL particle transits along the endosomal network to the LE/LY,
where it is hydrolyzed by acid lipase. Then, the free cholesterol
moves to the ER or returns to the PM via vesicular and non-
vesicular transport [1]. In addition, LDL-derived free cholesterol
may move to the plasma membrane without transiting to LE/LY
since acid lipase is also present in early endocytic organelles [2].
NPC arises from mutations in either NPC1 or NPC2, proteins of
unknown function that localize to the LE/LY at steady state and
are believed to play a role in cholesterol and/or lipid transport [3].
In NPC cells, LDL-cholesterol as well as endogenous cholesterol
and other lipids accumulate aberrantly in LE/LY compartments
and efflux of cholesterol, particularly LDL-derived cholesterol, is
greatly diminished [2,4–7]. Defects in membrane trafficking
accompany the NPC phenotype. In particular, cells lacking
NPC1 exhibit reduced recycling of lipid, protein, and fluid-phase
markers to the PM [2,8,9]. Since cholesterol homeostasis relies, in
part, on membrane recycling, an underlying problem in NPC may
be the inefficient recycling of cholesterol and other lipids. Thus,
modulation of this pathway represents a potential target for
correcting the aberrant cholesterol accumulation in the LE/LY
that is a hallmark of NPC disease.
ARF6 is a small GTPase that regulates the trafficking of
endosomal membrane [10]. Here we tested the hypothesis that
ARF6 activation enhances cholesterol efflux via its effect on early
endosome recycling, thereby reducing cholesterol accumulation
observed in NPC. We find that constitutively active ARF6 reverts
the NPC phenotype in part, including a decrease in filipin
intensity, an increase in cholesterol efflux, and a restoration of
normal sphingolipid trafficking. We also show that a concomitant
decrease in the amount of endogenous ARF6 that is GTP-bound
accompanies cholesterol storage in some NPC fibroblasts.
Furthermore, we show that the observed decrease in cholesterol
accumulation in NPC fibroblasts upon sustained ARF6 activation
correlates with their relative level of endogenous ARF6-GTP.
These studies support a role for ARF6 in lipid trafficking and
suggest that sustained stimulation of endosomal recycling increases
cholesterol efflux out of the cell, thereby decreasing intracellular
cholesterol accumulation.
Results and Discussion
Previous results suggest that cholesterol cycles, in part, through
vesicles containing the GTP-binding protein, ARF6, a potent
regulator of early endosomal membrane internalization and
recycling [10,11]. Consistent with these findings, we find
significant overlap of cholesterol with ARF6 in HeLa cells (Figure
S1A). To mimic abnormal cholesterol accumulation observed in a
variety of lipid storage diseases, we treated HeLa cells with the
hydrophobic polyamine U18666A. Treatment with U18666A
induces acute cholesterol accumulation that is indistinguishable
from that seen in NPC (Figure 1A) [12]. U18666A blocks
cholesterol exit from LE/LY likely by binding negatively charged
phospholipids in late endosomal membranes, such as LBPA
[13,14]. Since ARF6 activation is coupled to the efflux of recycling
endosomal membrane [10], we examined the impact of constitu-
tive ARF6 activation on the lipid accumulation phenotype induced
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5193Figure 1. Constitutively active ARF6 increases cholesterol removal in NPC-like cells. A, HeLa cells (with or without 1 mg/ml U18666A
treatment for 24 h) were fixed and stained with filipin. Note cholesterol accumulation in cells treated with U18666A. Bars, 20 mm. B, HeLa cells were
treated with U18666A to induce cholesterol accumulation and then transfected with pIRES-GFP encoding ARF6(Q67L), the ARF6-GTP mutant, or
ARF6(T27N), the ARF6-GDP mutant, and fixed approximately 24 h post-transfection. Left panels show GFP expression and right panels show filipin
staining. Transfected cells are marked with asterisks in filipin images. Bars, 20 mm. C, Quantitation of the percentage of transfected cells with reduced
filipin intensity (see Methods). For each condition, the average of three independent experiments is shown with standard error bars. The difference
between control cells and ARF6(Q67L)-expressing cells is statistically significant (p=0.021), using a two-tailed t-test. D, Relative cholesterol efflux from
HeLa cells treated with U18666A and then transfected with pIRES-GFP (EV) or pIRES-GFP encoding ARF6(Q67L) or ARF6(T27N). The average of three
independent experiments is shown with standard error bars. Statistically significant comparisons: ARF6(Q67L) vs. EV, p=0.024 and ARF6(Q67L) vs.
ARF6(T27N), p=0.037. The actual percentage of cellular cholesterol effluxed in each case: 2.41% for EV control, 2.56% for ARF6(T27N), and 3.18% for
ARF6(Q67L).
doi:10.1371/journal.pone.0005193.g001
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PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5193by U18666A. To this end, HeLa cells were transfected with a
GTPase defective, constitutively activated ARF6 mutant,
ARF6(Q67L), after incubation with U18666A for 6–8 h to induce
cholesterol accumulation. Cells were stained with filipin to
visualize cholesterol. Sustained ARF6 activation induced a marked
decrease in filipin staining compared to non-transfected cells in the
same experiment (Figure 1B, top row, and Figure S1B). To
quantitate the reduction in cholesterol accumulation induced by
sustained ARF6 activation, we measured the filipin intensity in
transfected and untransfected cells and found that approximately
60% of the cells expressing exogenous ARF6-GTP exhibited
reduced filipin intensity compared to non-transfected cells
(Figure 1C). In contrast, when cells were transfected with
ARF6(T27N), the dominant negative ARF6 mutant, no significant
change in filipin intensity was observed compared to untransfected
cells (Figure 1B, bottom row, and 1C).
Our results suggest that sustained activation of ARF6 induces
exit of cholesterol from LE/LY compartments. We propose that
cholesterol ‘‘trapped’’ in the LE/LY is accessible for removal in
response to modulation of upstream steps along the endosomal
pathway, in our case endosomal recycling. To test this hypothesis,
we determined whether sustained ARF6 activation promotes
cholesterol removal from U18666A-treated cells and measured
ABCA1-mediated cholesterol efflux. HeLa cells were incubated
with U18666A and transfected as described above and cholesterol
efflux was measured 24 hours later. Routine transfection efficiency
is between 50–60%. Upon sustained ARF6 activation, cholesterol
efflux increased by over 30% (Figure 1D). These results suggest
that ARF6 activation reduces cholesterol accumulation by
stimulating its movement to the plasma membrane and subsequent
removal, likely via its well-established role in endosomal
membrane recycling. In this way, stimulation of ARF6-mediated
endosomal recycling may act as a compensatory mechanism to
shift endosomal transport equilibrium in favor of recycling, in turn
alleviating cholesterol accumulation in the LE/LY.
Next, we investigated whether ARF6 is required for cholesterol
homeostasis under normal conditions. We depleted ARF6 protein
levels by transfecting cells with ARF6 siRNA and 48 h after
transfection, we examined cholesterol distribution. As shown in
Figure 2B, we found that siRNA-treated cells exhibited significant
cholesterol accumulation inside the cell as visualized by staining
with BCh (biotinylated h-toxin). Like filipin, BCh binds to
cholesterol-rich domains and is visualized using fluorescently
labeled streptavidin [15]. Compared to filipin staining, use of BCh
leads to less labeling of the cell surface, less perturbation of
membrane-lipid organization and more distinct labeling of
internal cholesterol membranes [15]. When co-transfected with
siRNA and a wild-type ARF6 construct bearing silent mutations in
the region targeted by RNAi, no cholesterol accumulation was
observed (Figure 2B, right panel). Using a biochemical assay to
measure cholesterol levels, we found that ARF6-depleted cells
exhibited greater than 65% increase in cholesterol after 48 h of
siRNA treatment (Figure 2C). These results show that ARF6 is
important for normal cholesterol homeostasis. These findings
support the idea that perturbations in membrane recycling—in
this case through the depletion of ARF6—can lead to cholesterol
accumulation.
Next we determined how sustained ARF6 activation impacts
cholesterol accumulation observed in fibroblasts derived from
NPC patients. Normal (GM05659) and NPC mutant fibroblasts
(GM03123, GM17923, and GM18436) were transfected with the
ARF6-GTP mutant, ARF6(Q67L). In each case, sustained ARF6
activation led to a reduction in filipin intensity (Figure 3A, top row,
and Figure S2). Notably, the extent of response to ARF6-GTP
expression varied among NPC fibroblasts derived from different
patients (Figure 3B). In GM03123 cells, we observed reduced
filipin intensity in 31% of transfected cells compared to
neighboring, non-transfected cells. However, less than 18% of
transfected GM17923 cells exhibited reduced filipin intensity and
even fewer GM18436 cells responded to sustained ARF6
activation with a reduction in filipin intensity (9%; Figure 3B).
In NPC cells, cholesterol-rich LE/LY compartments stain positive
for lysosome markers, such as Lamp1. We observed that
approximately 25% of the NPC cells expressing constitutively
active ARF6 display a pool of filipin staining with significantly
reduced overlap with Lamp1 (see arrows in Figure 3C and Figure
S3), consistent with the hypothesis that sustained activation of
ARF6 can lead to exit of cholesterol from the Lamp1-positive LE/
LY compartments. We found no change in filipin intensity or
overlap with Lamp1 in cells transfected with dominant negative
ARF6, ARF6(T27N) (Figure 3C, bottom row). To investigate
whether the varied response to ARF6 activation in NPC cells was
coupled to endogenous ARF6-GTP levels, we examined the levels
of endogenous ARF6-GTP using a GST-MT2 pull-down assay
[16]. In each case, we compared the ratio of ARF6-GTP to total
ARF6. Of the NPC fibroblasts we examined, GM03123 exhibited
greater than 30% reduction in the level of ARF6-GTP compared
to control cells, GM17923 had the same level as control cells, and
GM18436 had a higher level of ARF6-GTP (Figure 3C,D). Thus,
sustained ARF6 activation induced the most significant reduction
in cholesterol accumulation in the NPC fibroblasts with the lowest
endogenous levels of ARF6-GTP (GM03123).
We also investigated the impact of ARF6 activation on the
distribution of other lipids, such as glycosphingolipids, that traffic
inappropriately and accumulate with cholesterol in LE/LY
compartments in NPC [14,17]. We analyzed the distribution of
cholera toxin (Ctx) that binds to GM1 ganglioside at the PM and
serves as a marker for its localization. In normal cells, after
internalization Ctx targets to the Golgi via retrograde traffic,
whereas in NPC cells, Ctx accumulates instead in endosomal
vesicles throughout the cytoplasm. Cholesterol depletion using
methyl-b-cyclodextrin effectively restores normal Golgi targeting
of Ctx [17]. Thus we determined if the reduction in cholesterol
accumulation induced by sustained ARF6 activation is sufficient to
restore Golgi targeting of internalized Ctx. As seen in Figure 4A,
the efficiency of Ctx targeting to the Golgi in NPC fibroblasts was
noticeably reduced as evidenced by increased labeling of Ctx in
vesicles throughout the cytoplasm and in marked contrast with
control cells that showed efficient targeting of Ctx to the Golgi.
Next, we examined the effect of exogenous ARF6-GTP on Ctx
trafficking in NPC fibroblasts. We observed increased targeting of
Ctx to the Golgi, as evidenced by reduced Ctx label outside of the
Golgi (Figure 4B). We quantitated the percentage of Ctx label at
the Golgi compared to the total Ctx label in transfected and non-
transfected NPC fibroblasts. We found expression of constitutively
active ARF6 increased targeting of Ctx to the Golgi by 80–90%
(see Table 1). NPC cells expressing dominant negative ARF6,
ARF6(T27N), exhibited no change in Ctx targeting (Figure S4).
These findings suggest that the reduction in cholesterol storage
induced by sustained ARF6 activation allows for restoration of
normal lipid trafficking. Alternatively, ARF6 itself may be involved
in the trafficking of Ctx to the Golgi and expression of ARF6-GTP
may stimulate its transport to the Golgi.
Although lipid accumulation is a defining characteristic of NPC
cells, defects in the recycling of protein, lipid, and soluble ligands
accompany the NPC phenotype [8,9,17,18]. In addition to a
potential role for NPC1, an underlying cause for trafficking defects
in NPC may be changes in the activity of proteins that regulate
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PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5193Figure 2. Depletion of ARF6 promotes cholesterol accumulation in normal cells. HeLa cells were mock-treated with transfection reagent
alone or transfected with siRNA directed against ARF6 alone or plus pIRES-GFP-ARF6
si-res (‘‘Rescue’’) and analyzed 48 h later. A, ARF6 levels in cell
lysates were determined using Western Blot analysis and probing for mouse anti-a-tubulin antibody (loading control) and a monoclonal antibody
against ARF6. B, Cholesterol localization in fixed cells was assessed using BCh toxin and streptavidin conjugated to Alexa Fluor 594. All three images
were acquired in the same experiment using identical acquisition parameters. Contrast was enhanced using identical parameters in Adobe
Photoshop 7.0. Inset in last image displays GFP expression indicating cells transfected with pIRES-GFP-ARF6
si-res. Bars, 20 mm. C, Quantitation of
cholesterol concentration using colorometric assay (see Methods). Values shown are percent of control. For each condition, the average of four
independent experiments is shown with standard error bars. Statistically significant comparisons: ARF6 siRNA vs. control, p=0.056 and ARF6 siRNA
vs. Rescue, p=0.012, using a two-tailed t-test.
doi:10.1371/journal.pone.0005193.g002
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PLoS ONE | www.plosone.org 4 April 2009 | Volume 4 | Issue 4 | e5193Figure 3. Reduction in cholesterol accumulation induced by ARF6-GTP expression is coupled to endogenous ARF6-GTP levels in
NPC mutant fibroblasts. A, NPC mutant fibroblasts (GM03123, GM17923, and GM18436) were transfected with pIRES-GFP bearing ARF6(Q67L).
Cells were fixed approximately 24 h post-transfection and stained with filipin (pseudo-colored blue in merged image) and counterstained with
rhodamine phalloidin (red in merged image). Transfected cells are marked with asterisks in filipin images. Note decreased filipin staining in GFP-
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endosomal Rab GTPase that facilitates endosomal recycling, is
expressed at higher levels in NPC cells, but its activity is
compromised by a decrease in its ability to be extracted from
endosomal membranes [18]. In the present study we find that
levels of activated ARF6 are suppressed in fibroblasts derived from
an NPC patient. Thus, an inhibition of endosomal recycling due to
changes in the activity of regulatory proteins, such as ARF6, may
contribute directly to the NPC phenotype by promoting
cholesterol accumulation. This work is consistent with other
reports showing that Rab proteins involved in endosome
membrane cycling, such as Rab11 and Rab8, also impact normal
cholesterol dynamics [19,20].
Previous studies have shown that late endocytic traffic, mediated
by Rab7 and Rab9, is compromised in NPC cells [9,21,22].
Overexpression of Rab 7 and 9 proteins reduced the NPC
phenotype in cultured cells and in mice, suggesting that
stimulation of traffic out of the late endosome and lysosome may
bypass the block caused by NPC1 mutations [23–26]. Our findings
support the involvement of endosomal recycling in cholesterol
accumulation and identify that stimulation of endosomal recycling
reverses the NPC phenotype.
Finally, our results also demonstrate that cell lines derived from
different NPC patients display different relative levels of
endogenous ARF6-GTP. Furthermore, the reduction in choles-
terol accumulation we observe in response to sustained ARF6
activation varies inversely with the relative level of endogenous
ARF6-GTP. Thus, ARF6 activation compensates for the NPC
defect most effectively in the fibroblasts with the lowest levels of
endogenous ARF6-GTP. These findings suggest that changes in
membrane trafficking pathways or activities of associated regula-
tory proteins may contribute differently to individual cases of
NPC. Such variances among NPC cases should therefore be taken
into account when formulating therapeutic strategies aimed at
modulating the trafficking of cholesterol or other sphingolipids.
Methods
Reagents
Filipin III was obtained from Sigma or Cayman Chemical.
Rhodamine phalloidin, streptavidin conjugated to Alexa Fluor
594, cholera toxin subunit B (Ctx) conjugated to Alexa FluorH 555
and anti-mouse secondary antibody conjugated to Cy5 were from
Invitrogen. Apolipoprotein AI and rabbit polyclonal antibody
against the hemagglutinin (HA) tag were from Sigma Chemical,
U18666A from Calbiochem and [1,2-
3H-(N)]-cholesterol from
Perkin Elmer. BCh toxin was provided by Yoshiko Ohno-Iwashita
(Tokyo, Japan). Mouse monoclonal antibody against GM130 was
from BD Biosciences Pharmingen.
Cell culture and plasmid transfection
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
penicillin, and streptomycin (complete DMEM). Three primary
human skin fibroblastlines derived from NPC1 patients (GM03123,
GM18436, GM17923) and one primary human skin fibroblast line
from an unaffected patient (GM05659) were obtained from Coriell
Cell Repositories (Camden, NJ). They were cultured in Minimum
Essential Medium with Earle’s salts (Mediatech) with 2 mM L-
glutamine, 10% fetal bovine serum, penicillin, and streptomycin.
pcDNA3.1 bearing HA-tagged ARF6 and pIRES-EGFP bearing
ARF6(T27N) or ARF6(Q67L) have been previously described
[16,27]. Transient plasmid transfections were performed using
FuGENE transfection reagent (Roche Molecular Biochemicals),
following the manufacturer’s instructions.
Filipin fluorescence and BCh-toxin staining
For filipin staining, cells were fixed with 2%PFA for 30 min,
washed with 1XPBS, and incubated with freshly prepared filipin
solution (,200 mg/ml in PBS containing 10% fetal bovine serum)
for 30 minutes. Then, cells were washed with PBS and mounted in
ProLong Anti-fade mounting media (Invitrogen) or processed for
immunofluorescence. Cells were observed on an inverted
microscope (Eclipse TE2000-U; Nikon) fitted for immunofluores-
cence with a 606 immersion lens and HighQ filter sets from
Chroma (Brattleboro, VT). Images were acquired and analyzed
using Metamorph 6.2r4 (Universal Imaging Corp.) and a Cascade
512B camera (Photometrics). To measure filipin intensity, regions
of interest were drawn around each cell and the total pixel
intensity for each cell was recorded using ImageJ. 40–60 cells were
analyzed per experiment and three independent repetitions were
performed for each transfection. We scored a cell with reduced
filipin intensity if it displayed more than 30% reduction in filipin
intensity compared with the average filipin intensity of untrans-
fected cells from the same experiment. For BCh labeling, cells
were fixed with 4% PFA and stained with BCh and Alexa594-
conjugated streptavidin as described [15]. Cells labeled with BCh
were imaged on a Bio-Rad MRC1024 confocal system equipped
with a Nikon Diaphot 200 fluorescence microscope. Images were
adjusted for contrast using identical parameters in Adobe Photo-
shop, version 7.0.
Cholesterol efflux
HeLa cells were seeded in a 12-well dish at 60% confluency.
The next day cells were incubated with serum-free DMEM
containing
3H-cholesterol (1 mCi/ml) and 0.2% BSA for 17 h.
Then, U18666A (1 mg/ml) was added to the cells and they were
incubated for another 7 h. Next, cells were transfected with the
appropriate plasmid. After 2 h, transfection complexes were
removed, and cells were incubated with fresh complete DMEM
containing
3H-cholesterol (1 mCi/ml), 0.2% BSA and U18666A
for 4–6 hours. Then, media was removed and cells were washed
extensively with 1XPBS. To monitor efflux, cells were incubated
with serum-free DMEM supplemented with apoA-I (10 mg/ml)
+0.2%BSA and U18666A for 14 h, after which time media
positive cells. B, NPC mutant fibroblasts (GM03123, GM17923 and GM18436) were treated as in A. Transfected cells with filipin intensity that was lower
than neighboring non-transfected cells (as depicted in A) were scored (see Methods). 80–100 transfected cells of each cell line were counted in each
of three independent experiments. The average percentage of transfected cells displaying reduced filipin intensity is graphed. Standard error bars are
shown. Statistically significant comparisons: GM03123 vs. GM17923, p=0.0117 and GM03123 vs. GM18436, p=0.0114. C, GM03123 cells were
transfected with pIRES-GFP bearing ARF6(Q67L) (top row) or ARF6(T27N) (bottom row). Cells were fixed approximately 24 h post-transfection and
stained with filipin (pseudo-colored green in merged image) and immunolabeled for Lamp1 (red in merged image). Bars, 20 mm. Arrow points to
region where filipin staining no longer overlaps with Lamp1. D, Lysates were prepared from normal (GM05659) and NPC mutant fibroblasts
(GM03123, GM17923, GM18436) and subjected to the GST-MT-2 pull-down assay and probed for ARF6. Top row is ARF6 precipitated with GST-MT-2
beads and bottom row is ARF6 from the total cell lysate. E, Immunoblots from three independent experiments were subjected to densitometric
analysis and the ARF6-GTP/total ARF6 ratios were calculated and normalized to control levels (GM05659). Standard error bars are shown. Statistically
significant comparisons: GM03123 vs. GM05659, p=0.011 and GM18436 vs. GM05659, p=0.022.
doi:10.1371/journal.pone.0005193.g003
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to remove cell debris. Cells were lysed with 0.2N NaOH. The
radioactivity in each fraction (media and cell lysate) was
determined using a Beckman scintillation counter. Percent efflux
was calculated as follows: (media cpm)/(cell lysate cpm + media
cpm). Each experiment was carried out in triplicate and three
independent repetitions were performed. The average efflux
percents were compared using a two-tailed student’s t-test (see
Figure 1E).
RNA interference and rescue
Endogenous levels of ARF6 were knocked-down in HeLa cells
using siRNA oligonucleotides [28]. To create an siRNA-resistant
ARF6 construct (for ‘‘rescue’’ experiments), pIRES-GFP bearing a
wild-type copy of ARF6 was used for site-directed mutagenesis
using the Stratagene QuikChange II kit. Mutagenesis introduced
three silent mutations in ARF6 at the following nucleotide
positions: A84C, C87A, G90A. Successful clones were confirmed
by DNA sequencing. Fourty-eight hours after transfection,
approximately 1610
6 cells were trypsinized and a small portion
was used to make a protein lysate for Western blotting analysis.
The remaining cells were used for lipid isolation and quantitation
of cholesterol concentration using the colorometric Cholesterol/
Cholesteryl Ester Quantitation Kit (Calbiochem). For this analysis,
no esterase was added to the assay and the absorbance was read at
570 nm.
Determination of relative ARF6-GTP levels
Cell lysates were prepared, subjected to the MT-2 pull-down
assay, and analyzed by immunoblotting as described previously
[16], using approximate 450 mg of protein lysate per assay.
Western blots were scanned with an UltraScan XL laser
Densitometer (Amersham Biosciences) and ARF6 precipitated
with MT-2 was normalized to total ARF6 levels in the lysate. In
each experiment, the level of ARF6-GTP in control cells
(GM05659) was set to 1 and the levels in each NPC cell line
relative to control is reported under ‘‘Results’’ (Figure 2D). The
averages from three independent experiments were compared
using a two-tailed student’s t-test (see Figure 3D).
Cholera toxin trafficking
Cells were incubated with 1.5 mg/ml CtxB-Alexa Fluor 555 in
PBS for 30 minutes at 4uC, washed three times with PBS, and
incubated in serum-free media for 1 hour at 37uC prior to fixation.
To localize the Golgi, cells were labeled subsequently for GM130
using a mouse monoclonal antibody and Cy5-conjugated
secondary antibody. Immunofluorescence techniques have been
described previously [29]. To determine the percentage of Ctx
localized to the Golgi, individual cells were examined using ImageJ
and the total pixel intensity of the Ctx label within the Golgi was
divided by the total pixel of the Ctx label in the entire cell. Results
are presented in Table 1.
Supporting Information
Figure S1 Cholesterol overlaps with ARF6 in HeLa cells and
sustained activation of ARF6 decreases cholesterol accumulation.
A, HeLa cells were transfected with HA-tagged ARF6(wt), fixed
and stained with filipin (top right; pseudo-colored green in merged
image) and immunolabeled for HA-tagged ARF6 (top left; red in
merged image). Bottom right is an enlarged region of the merged
image outlined with a white rectangle. Bar, 20 mm. B, HeLa cells
were treated with U18666A to induce cholesterol accumulation
and then transfected with pIRES-GFP bearing ARF6(Q67L), fixed
approximately 18 h post-transfection, and stained with filipin (red
in merged image). Transfected cells are marked with asterisks in
filipin images. Note decreased filipin staining in GFP-positive cells.
Found at: doi:10.1371/journal.pone.0005193.s001 (3.15 MB TIF)
Figure S2 ARF6-GTP expression reduces cholesterol accumu-
lation in NPC fibroblasts. NPC mutant fibroblasts (GM03123,
GM17923 and GM18436) were transfected with pIRES-GFP
bearing ARF6(Q67L) (left panel). Cells were fixed approximately
24 h post-transfection and stained with filipin (right panel).
Transfected cells are marked with asterisks in filipin images. Bars,
20 mm.
Found at: doi:10.1371/journal.pone.0005193.s002 (1.85 MB TIF)
Figure S3 NPC fibroblasts expressing ARF6-GTP display
regions of filipin staining that are Lamp1-negative. NPC mutant
fibroblasts (GM03123-left column and GM17923-right column)
Figure 4. ARF6-GTP expression restores sphingolipid targeting to the Golgi. A, CtxB-AlexaFluor555 internalization in control (GM05659)
and NPC mutant fibroblasts (GM03123, GM17923, and GM18436) was performed as described in Methods. To localize the Golgi, cells were fixed and
immuno-labeled for GM130 with a mouse monoclonal antibody and a Cy5-conjugated anti-mouse secondary antibody (pseudo-colored green). B,
Control and NPC mutant fibroblasts were transfected with ARF6(Q67L)-pIRES-GFP (monochrome, third row from left), subjected to CtxB-
AlexaFluor555 internalization 20 h post-transfection, and immuno-labeled for GM130 (pseudo-colored green) as described in A. Transfected cells are
marked with asterisks in merged images. See Table 1 for quantification of Golgi targeting of Ctx in NPC fibroblasts transfected with ARF6(Q67L)-
pIRES-GFP.
doi:10.1371/journal.pone.0005193.g004
Table 1. Golgi targeting of internalized Ctx in NPC mutant fibroblasts. NPC fibroblasts were transfected with ARF6(Q67L)-pIRES-
GFP and Ctx internalization was analyzed (as in Figure 4B). The percentage of Ctx localized to the Golgi, as described in Methods, is
shown here.
NPC Fibroblast Line Percentage of Ctx label in the Golgi (average percent6SD)
Percent Increase in Golgi
targeting of Ctx
Non-transfected ARF6(Q67L)-transfected
GM03123 8.361.4 15.164.6 81%
GM17923 9.361.9 18.064.6 94%
GM18436 9.762.2 18.566.7 91%
doi:10.1371/journal.pone.0005193.t001
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approximately 24 h post-transfection and stained with filipin
(pseudo-colored green in merged image) and immunolabeled for
Lamp1 (red in merged image). Arrows point to areas of filipin
staining that no longer overlap with Lamp1.
Found at: doi:10.1371/journal.pone.0005193.s003 (3.12 MB TIF)
Figure S4 ARF6-GDP expression in control and NPC mutant
fibroblasts does not affect CtxB traffic to the Golgi. Control
(GM05659, top row) and NPC mutant fibroblasts (GM03123,
bottom row) were transfected with ARF6(T27N)-pIRES-GFP
(monochrome, third row from left) and subjected to CtxB-
AlexaFluor555 internalization 20 h post-transfection as described
in Methods. Cells were fixed and immunolabeled for GM130 with
a mouse monoclonal antibody and a Cy5-conjugated anti-mouse
secondary antibody (pseudo-colored green in merged image).
Transfected cells are marked with asterisks in merged images. Bar,
20 mm
Found at: doi:10.1371/journal.pone.0005193.s004 (2.48 MB TIF)
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